GLP-1-RA reduces cancer risk in patients with diabetes more than insulin

Photo of author
Written By Kampretz Bianca

Lorem ipsum dolor sit amet consectetur pulvinar ligula augue quis venenatis. 

dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct dct

Cancers associated with obesity

If people with type 2 diabetes are given GLP-1 receptor agonists, it appears that this may reduce the risk of developing obesity-related cancers. However, this only applies to the comparison with insulin, not metformin.

Source link

Leave a Comment

fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle fle